Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Sara Dellasala
Long-Term Molecular and Cytogenetic Response and Survival Outcomes With Imatinib 400 Mg, Imatinib 800 Mg, Dasatinib, and Nilotinib in Patients With Chronic-Phase Chronic Myeloid Leukaemia: Retrospective Analysis of Patient Data From Five Clinical Trials
The Lancet Haematology
Hematology
Long-Term Follow-Up of Lower Dose Dasatinib (50 Mg Daily) as Frontline Therapy in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia
Cancer
Cancer Research
Oncology
Related publications
Long-Term Impact of Molecular Response Fluctuations in Chronic Myeloid Leukaemia Patients Treated With Imatinib
British Journal of Haematology
Hematology
Therapeutic Drug Monitoring of Imatinib, Nilotinib, and Dasatinib for Patients With Chronic Myeloid Leukemia
Biological and Pharmaceutical Bulletin
Medicine
Pharmacology
Pharmaceutical Science
Cost-Effectiveness of Dasatinib and Nilotinib for Imatinib-Resistant or -Intolerant Chronic Phase Chronic Myeloid Leukemia
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Complete Molecular Response Induced by Nilotinib in a Patient Previously Treated With Imatinib, Nilotinib and Dasatinib
Clinical Management Issues
Medicine
Accounting
Management
Business
Long-Term Molecular Responses to Imatinib in Patients With Chronic Myeloid Leukemia: Comparison Between Complete Cytogenetic Responders Treated in Early and in Late Chronic Phase
Haematologica
Hematology
Modelling Predictors of Molecular Response to Frontline Imatinib for Patients With Chronic Myeloid Leukaemia
PLoS ONE
Multidisciplinary
Long-Term Safety and Efficacy of Dasatinib in the Treatment of Chronic-Phase Chronic Myeloid Leukemia Patients Resistant or Intolerant to Imatinib
Blood and Lymphatic Cancer: Targets and Therapy
Gynaecomastia in Men With Chronic Myeloid Leukaemia After Imatinib
The Lancet
Medicine
Long-Term Efficacy and Safety of Dasatinib in Patients With Chronic Myeloid Leukemia in Accelerated Phase Who Are Resistant to or Intolerant of Imatinib
Blood Cancer Journal
Oncology
Hematology
